Our data showed that XRCC4 level is significantly correlated with PFS in ovarian cancer patients, and targeting XRCC4 or the upstream kinase JNK strongly attenuated the cisplatin-resistant tumor growth of ovarian cancer cells in the preclinical mouse model. This evidence concerns the gene XRCC4 and ovarian carcinoma.